Off
Did you know?
Cimzia® is indicated for the treatment of adult patients with severe active axial spondyloarthritis, comprising1:
- Ankylosing spondylitis (AS) (also known as radiographic axial spondyloarthritis)
- Adults with severe active ankylosing spondylitis who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs)
- Axial spondyloarthritis without radiographic evidence of AS (also known as non-radiographic axial spondyloarthritis)
- Adults with severe active axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C-reactive protein (CRP) and /or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to NSAIDs
These are not the full licensed indications of Cimzia®. Please refer to the SmPC for further information.
Orbit 360 enabled
Off
Off
Key studies
Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo (C-OPTIMISE)
Key study
Study design
See Also
Off
Efficacy
See the wealth of efficacy data offered by Cimzia in axSpA: Key Efficacy Trial Data
Key study
Efficacy by section
See Also
Off
Dosing
Dosing and administration across all indications1
Key study
Dosing guide
Off
Distinct molecular structure
Off
Women of childbearing age
Reducing the burden for women of childbearing age
Due to the emerging biosimilar market, trusts are being encouraged to use the best value biologic.9 In addition to financial costs, it is important to consider the wider impact on the patient, their family and the NHS when a patient is on a treatment journey e.g. switching treatments, repeated hospital visits, loss of work days.9
Cimzia should be only be used during pregnancy if clinically needed.1 Before initiating Cimzia, please check SmPC.
Orbit 360 enabled
Off
*79.0% (83/105) of patients on reduced maintenance dose displayed sustained remission.2
† Sustained remission was defined as ASDAS <1.3 at Week 32 or 36, and at Week 48 with ASDAS <2.1 for Weeks 32 and 36.2.
‡ The recommended maintenance dose is 200mg Q2W, or 400mg Q4W. Reduced dosage of 200mg Q4W may be considered in patients in sustained remission after 1 year of treatment with certolizumab pegol.1
Orbit 360 enabled
Off
Off
References
- Cimzia® Summary of Product Characteristics. [Accessed February 2023].
- Landewé R, et al. Ann Rheum Dis. 2020;79(7):920–928.
- Enbrel® Summary of Product Characteristics. [Accessed February 2023].
- Remicade® Summary of Product Characteristics. [Accessed February 2023].
- Humira® Summary of Product Characteristics. [Accessed February 2023].
- Cosentyx® Summary of Product Characteristics. [Accessed February 2023].
- Taltz® Summary of Product Characteristics. [Accessed February 2023].
- Simpon® Summary of Product Characteristics. [Accessed February 2023].
- NHS England 2017 Commissioning framework for biological medicines (including biosimilar medicines) https://www.england.nhs.uk/wp-content/uploads/2017/09/biosimilar-medicines-commissioning-framework.pdf [Accessed February 2023]
Orbit 360 enabled
Off
Off
Because we're in this together...
Report adverse events
Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk and hpra.ie/homepage/about-us/report-an-issue.
Adverse events should also be reported to UCB Pharma Ltd Email: UCBCares.UK@ucb.com and UCBCares.IE@ucb.com.
Feature requests
Help us to grow our resource the way you want it to grow.
Date of preparation: February 2023
IE-P-CZ-AS-2100009